Analyst Price Targets — NERV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 1, 2025 8:10 pm | — | Jefferies | $5.00 | $3.80 | TheFly | Minerva price target raised to $5 from $3 at Jefferies |
| August 7, 2024 6:09 am | Douglas Tsao | H.C. Wainwright | $5.00 | $2.94 | TheFly | Minerva price target lowered to $5 from $7 at H.C. Wainwright |
| May 2, 2024 6:49 am | Douglas Tsao | H.C. Wainwright | $7.00 | $2.40 | StreetInsider | Minerva Neurosciences (NERV) PT Lowered to $7 at H.C. Wainwright |
Latest News for NERV
Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy
BURLINGTON, Mass. , June 01, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the formation of its Scientific Advisory Board (SAB), fulfilling a commitment made in connection with the Company's PIPE financing announced on October 21, 2025.
Minerva Neurosciences (NERV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The heavy selling pressure might have exhausted for Minerva Neurosciences (NERV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
BURLINGTON, Mass. , May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman and Chief Executive Officer, will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NERV.
U.S. House Trading
No House trades found for NERV.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.